Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: A meta-analysis

Table 1 Characteristics of trials included in meta-analysis

Study	Patients (S-1/capecitabine)	S-1 regimen	Capecitabine regimen
Kim et al[23]	65/64	S-1 80 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle	Capecitabine 2000 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle
Lee et al[22]	42/44	S-1: BSA < 1.25 m2, 80 mg/d;	Capecitabine
		BSA: 1.25-1.5 m2, 100 mg/d;	2500 mg/m2 per day
		BSA > 1.5 m2, 120 mg/d; d1-28 42-d cycle	d1-14 21-d cycle
Zhang et al[21]	41/40	S-1 80 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle	Capecitabine 2000 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle
Xiong et al[20]	42/44	S-1 80 mg/m2 per day d1-14 + docetaxel 25 mg/m2 d1, 8, 15 28-d cycle	Capecitabine 1250 mg/m2 per day d1-14 + docetaxel 25 mg/m2 d1, 8, 15 28-d cycle

Table 2 Trial and patient characteristics

Study	Disease stage	Follow-up months	Trial randomization	Lost to follow-up	Survival analysis
Kim et al[23]	Advanced gastric cancer, chemotherapy-naive	0.5-39.2	Yes	Recorded	ITT
Lee et al[22]	Elderly patients (aged ≥ 65 yr) Advanced gastric cancer	Capecitabine: 21.9; S-1: 21.7	Yes	Recorded	ITT
Zhang et al[21]	Gastric cancer after surgery	24	Yes	Recorded	Evaluable
Xiong et al[20]	Advanced gastric cancer, chemotherapy-naive	2-28	Yes	Recorded	ITT